Federal Register · Regulatory notice
Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
This proposed rule would revise the Medicare Hospital Outpatient Prospective Payment System (OPPS) and the Medicare Ambulatory Surgical Center (ASC) payment system for calendar year 2027 based on our continuing experience with these systems. We also describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment systems. In addition, this proposed rule would update and refine the requirements for the Hospital Outpatient Quality Reporting Program and the Ambulatory Surgical Center Quality Reporting Program. There are no changes to the Rural Emergency Hospital Quality Reporting Program. We propose to expand the prior authorization requirement to include additional Botulinum Toxin Injection services. We also propose to implement certain provisions of the Consolidated Appropriations Act, 2026, for off-campus outpatient departments of a provider. In addition, this proposed rule announces notices of closure of teaching hospitals and opportunities to apply for available slots. This rule also requests information regarding potential approaches to improve comparability and standardization, particularly for complex contracting methodologies, of the HPT information reported in machine- readable files and consumer-friendly displays. We propose hospital AOs with deeming authority to assess compliance with certain Emergency Medical Treatment and Labor Act (EMTALA) administrative requirements during accreditation and reaccreditation surveys. Finally, we are soliciting comments on a potential separate payment under the Inpatient Prospective Payment System (IPPS) for domestic procurement of personal protective equipment and essential medicines.
Follow ABT- Became public
- Jul 7, 2026
- Event / period date
- Not stated
- Collected
- Nov 8, 2026, 6:28 PM EST
Why this is connected
The source explicitly mentions ABBOTT LABORATORIES. A mention alone does not establish a financial benefit.
Source evidence
Read the source excerpt or record
the CY 2020 OPPS/ASC final rule with comment period, we finalized an alternative pathway for devices that are granted a Breakthrough Device designation (84 FR 61295) and receive FDA marketing authorization for the indication covered by the Breakthrough Device designation. Under this alternative pathway, devices that are granted an FDA Breakthrough Device designation are not evaluated in terms of the current substantial clinical improvement criterion at Sec. 419.66(c)(2) for the purposes of determining device pass-through payment status, but do need to meet the other requirements for pass- through payment status in our regulation at Sec. 419.66. Devices that are part of the Breakthrough Devices Program, have received FDA marketing authorization for the indication covered by the Breakthrough Devices designation, and meet the other criteria in the regulation can be approved through the quarterly process and announced through that process (81 FR 79655). Proposals regarding these devices and whether pass-through payment status should continue to apply are included in the next applicable OPPS rulemaking cycle. As discussed in the FY 2027 IPPS/LTCH PPS proposed rule (91 FR 19457 to 19459), we have proposed to repeal the alternative pathway for new technology add-on payment and OPPS device pass-through applications and require all applicants for new technology add-on payments and OPPS
Congressional trading in ABT
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 30, 2026$1K–$15K
Rep. Thomas H. Kean, Jr. (R-NJ-7)
Sold (partial) Abbott Laboratories ABT
$1K–$15K · Traded Sep 17, 2026 · disclosed Oct 30, 2026
Committee overlap: Energy and Commerce - Oct 27, 2026$50K–$100K
Rep. Pete Sessions (R-TX-17)
$50K–$100K · Traded Oct 2, 2026 · disclosed Oct 27, 2026 · Spouse
- Oct 12, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Abbott Laboratories ABT
$1K–$15K · Traded Sep 18, 2026 · disclosed Oct 12, 2026
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Abbott Laboratories ABT
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 18, 2026$15K–$50K
Rep. Rick W. Allen (R-GA-12)
$15K–$50K · Traded Jul 14, 2026 · disclosed Aug 18, 2026 · Spouse
Committee overlap: Energy and CommerceTraded 2 days before earnings - Aug 14, 2026$1K–$15K
Rep. Richard McCormick (R-GA-7)
$1K–$15K · Traded Jul 30, 2026 · disclosed Aug 14, 2026
Got $2K from the company’s PAC - Aug 12, 2026$1K–$15K
Rep. Mike Kelly (R-PA-16)
$1K–$15K · Traded Jul 17, 2026 · disclosed Aug 12, 2026 · Spouse
- Jul 21, 2026$15K–$50K
Sen. Alan Armstrong (R-OK)
Sold (full) Abbott Laboratories ABT
$15K–$50K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.